ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2653

Results of a Comprehensive Review of Pulmonary Function and Safety Data in a Phase IIb Clinical Program Testing Anti-GM-CSF Receptor Antagonist Mavrilimumab for Treatment of RA

GR Burmester1, MA Michaels2, D Close3, A Godwood3, K Middleton3, P Miranda4, J Vencovský5, JM Kremer6, IB McInnes7, M Albulescu^3 and Michael Weinblatt8, 1Charité – University Medicine Berlin, Berlin, Germany, 2MedImmune, Gaithersburg, MD, 3MedImmune, Cambridge, United Kingdom, 4Centro De Estudios Reumatológicos, Santiago, Chile, 5Charles University, Prague, Czech Republic, 6The Albany Medical College, Albany, NY, 7University of Glasgow, Glasgow, United Kingdom, 8Brigham and Women’s Hospital, Boston, MA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: pulmonary complications, rheumatoid arthritis (RA) and treatment

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 15, 2016

Session Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: RA is associated with significant pulmonary comorbidity and declines in lung function over time; but longitudinal assessment of pulmonary abnormalities in the context of RA treatment needs further characterization. Mavrilimumab, an investigational human monoclonal antibody, inhibits GM-CSF by binding to the GM-CSF receptor α subunit. We investigated pulmonary safety of mavrilimumab because of its potential to inhibit alveolar macrophage function.

Methods: Pulmonary monitoring included standardized lung function testing (spirometry and diffusing capacity of lung carbon monoxide [DLCO]), chest X-rays, assessments of dyspnea and pulmonary adverse events (AEs) in two randomized, double-blind, multicenter studies (NCT01706926; NCT01715896) where pts with moderate to severe RA received mavrilimumab or placebo and mavrilimumab or golimumab, respectively, and the long-term open-label extension (NCT01712399) where all received mavrilimumab. All studies excluded pts with clinically significant uncontrolled pulmonary disease. Adjudication of lung function abnormalities and pulmonary AEs was by an Independent Pulmonary Expert Committee.

Results: The 442 pts receiving mavrilimumab had cumulative safety data exposure of approximately 900 pt-yrs and median (min–max) exposure of 2.5 (0.1–3.3) yrs. Baseline (BL) characteristics are shown in the Table. Mean forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), DLCO (Figure), and dyspnea (Table) were mostly maintained within 5% of BL values for pts treated during the randomized phases of NCT01706926 and NCT01715896. Few pts showed clinically significant (>20% from BL and <80% predicted) decreases in predicted FEV1 and FVC (Table); these were mostly transient. Overall, 83 pts (9.24/100 pt-yrs) reported ≥1 pulmonary AE; bronchitis was reported most frequently (pts [per 100 pt-yrs]: 34 [3.78]), followed by respiratory tract infection and cough (14 [1.56] and 12 [1.34], respectively). The rate of pulmonary AEs reported was generally stable over time. No suspected/confirmed pulmonary alveolar proteinosis cases, no pulmonary-related deaths, and only one treatment-related pulmonary serious AE (acute bronchitis) were reported.

Conclusion: Many pts with BL pulmonary comorbidities were identified. Mavrilimumab was not associated with substantial effects on pulmonary function; the rate of pulmonary AEs was stable during the study. This may be the most comprehensive longitudinal study of pulmonary function in RA; further long-term studies should fully characterize these findings and any impact of therapies. ^Joint senior authors.


Disclosure: G. Burmester, UCB, 2,AbbVie, 5,BMS, 5,Hexal, 5,Janssen Pharmaceutica Product, L.P., 5,Lilly, 5,MSD, 5,MadImmune, 5,Novartis Pharmaceutical Corporation, 5,Pfizer Inc, 5,Roche Pharmaceuticals, 5,AbbVie, 8,BMS, 8,Hexal, 8,MSD, 8,Novartis Pharmaceutical Corporation, 8,Pfizer Inc, 8,Roche Pharmaceuticals, 8; M. Michaels, AstraZeneca, 3,MedImmune, 3; D. Close, MedImmune Ltd, 1,MedImmune Ltd, 3; A. Godwood, AstraZeneca, 1,MedImmune, 3; K. Middleton, None; P. Miranda, MedImmune, 5; J. Vencovský, None; J. Kremer, MedImmune, 5; I. McInnes, MedImmune, 5; M. Albulescu^, MedImmune, 1,MedImmune, 3; M. Weinblatt, Amgen, 2,Crescendo bioscience, 2,Bristol myers squibb, 2,UCB, 2,Amgen, 5,AbbVie, 5,Roche Pharmaceuticals, 5,AstraZeneca, 5,MedImmune, 5,Paizer, 5,Lilly, 5,UCB, 5.

To cite this abstract in AMA style:

Burmester G, Michaels M, Close D, Godwood A, Middleton K, Miranda P, Vencovský J, Kremer J, McInnes I, Albulescu^ M, Weinblatt M. Results of a Comprehensive Review of Pulmonary Function and Safety Data in a Phase IIb Clinical Program Testing Anti-GM-CSF Receptor Antagonist Mavrilimumab for Treatment of RA [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/results-of-a-comprehensive-review-of-pulmonary-function-and-safety-data-in-a-phase-iib-clinical-program-testing-anti-gm-csf-receptor-antagonist-mavrilimumab-for-treatment-of-ra/. Accessed April 11, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/results-of-a-comprehensive-review-of-pulmonary-function-and-safety-data-in-a-phase-iib-clinical-program-testing-anti-gm-csf-receptor-antagonist-mavrilimumab-for-treatment-of-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.